Log in

Relevant bibliographies by topics / Plasmacytoid dendritic cell, metastatic melanoma / Journal articles

To see the other types of publications on this topic, follow the link: Plasmacytoid dendritic cell, metastatic melanoma.

Journal articles on the topic 'Plasmacytoid dendritic cell, metastatic melanoma'

Author: Grafiati

Published: 11 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Plasmacytoid dendritic cell, metastatic melanoma.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Monti, Matilde, Raffaella Vescovi, Francesca Consoli, et al. "Plasmacytoid Dendritic Cell Impairment in Metastatic Melanoma by Lactic Acidosis." Cancers 12, no. 8 (2020): 2085. http://dx.doi.org/10.3390/cancers12082085.

Full text

Abstract:

The introduction of targeted therapies and immunotherapies has significantly improved the outcome of metastatic melanoma (MM) patients. These approaches rely on immune functions for their anti-melanoma response. Plasmacytoid dendritic cells (pDCs) exhibit anti-tumor function by production of effector molecules, type I interferons (I-IFNs), and cytokines. Tissue and blood pDCs result compromised in MM, although these findings are still partially conflicting. This study reports that blood pDCs were dramatically depleted in MM, particularly in patients with high lactate dehydrogenase (LDH) and hi

APA, Harvard, Vancouver, ISO, and other styles

2

Ye, Juan, Herui Wang, Samik Chakraborty, et al. "Optimizing rWTC-MBTA Vaccine Formulations, Dosing Regimens, and Cryopreservation Techniques to Enhance Anti-Metastatic Immunotherapy." International Journal of Molecular Sciences 26, no. 3 (2025): 1340. https://doi.org/10.3390/ijms26031340.

Full text

Abstract:

Metastatic cancer poses significant clinical challenges, necessitating effective immunotherapies with minimal systemic toxicity. Building on prior research demonstrating the rWTC-MBTA vaccine’s ability to inhibit tumor metastasis and growth, this study focuses on its clinical translation by optimizing vaccine composition, dosing regimens, and freezing techniques. The vaccine formula components included three TLR ligands (LTA, Poly I:C, and Resiquimod) and an anti-CD40 antibody, which were tested in melanoma and triple-negative breast cancer (TNBC) models. The formulations were categorized as r

APA, Harvard, Vancouver, ISO, and other styles

3

Gerlini, Gianni, Carmelo Urso, Giulia Mariotti, et al. "Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes." Clinical Immunology 125, no. 2 (2007): 184–93. http://dx.doi.org/10.1016/j.clim.2007.07.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Pashenkov, Mikhail, Gerda Goëss, Christine Wagner, et al. "Phase II Trial of a Toll-Like Receptor 9–Activating Oligonucleotide in Patients With Metastatic Melanoma." Journal of Clinical Oncology 24, no. 36 (2006): 5716–24. http://dx.doi.org/10.1200/jco.2006.07.9129.

Full text

Abstract:

Purpose The recent identification of toll-like receptors (TLRs) and respective ligands allows the evaluation of novel dendritic cell (DC) –activating strategies. Stimulation of TLR9 directly activates human plasmacytoid DCs (PDCs) and indirectly induces potent innate immune responses in preclinical tumor models. We performed an open-label, multicenter, single-arm, phase II pilot trial with a TLR9-stimulating oligodeoxynucleotide in melanoma patients. Patients and Methods Patients with unresectable stage IIIb/c or stage IV melanoma received 6 mg PF-3512676 weekly by subcutaneous injection for 2

APA, Harvard, Vancouver, ISO, and other styles

5

Royal, Richard Eldon, Luis M. Vence, Tara Wray, et al. "A toll-like receptor agonist to drive melanoma regression as a vaccination adjuvant or by direct tumor application." Journal of Clinical Oncology 35, no. 15_suppl (2017): 9582. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.9582.

Full text

Abstract:

9582 Background: Toll like receptor (TLR) agonists may enhance vaccination or direct immune activation at the tumor microenvironment. This trial evaluates the biologic and clinical effects of Resiquimod, a TLR 7/8 agonist that can activate both myeloid (mDC, TLR 8) and plasmacytoid (pDC, TLR 7) dendritic cells, in patients with advanced stage melanoma. Methods: Class I HLA-A0201+ subjects with in-transit melanoma metastases or high risk for recurrence were vaccinated weekly with peptide vaccination (class I restricted peptide GP100209-2m and, if HLA-DP4+, also with class II restricted peptide

APA, Harvard, Vancouver, ISO, and other styles

6

Hanks, Brent Allen, Alisha Holtzhausen, Petra Gimpel та ін. "Effect of the loss of the type III TGFβ receptor during tumor progression on tumor microenvironment: Preclinical development of TGFβ inhibition and TGFβ-related biomarkers to enhance immunotherapy efficacy." Journal of Clinical Oncology 30, № 15_suppl (2012): 10563. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10563.

Full text

Abstract:

10563 Background: Overall, the clinical efficacy of tumor immunotherapy has been limited. Our incomplete understanding of the complex interplay between tumors and the immune microenvironment has contributed to these modest outcomes. Our work has revealed that several tumors downregulate the expression of the type III TGFβ receptor (TβRIII) with progression. TβRIII is shed from the cell surface to generate soluble TβRIII (sTβRIII) which is capable of sequestering TGFβ. Methods and Results: Using both breast cancer and melanoma tumor models we have demonstrated that the loss of TβRIII expression

APA, Harvard, Vancouver, ISO, and other styles

7

Wong, Deborah J. L., Aru Panwar, Ari Rosenberg, et al. "CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma." Journal of Clinical Oncology 39, no. 15_suppl (2021): TPS6089. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.tps6089.

Full text

Abstract:

TPS6089 Background: PD-1 blockade ± chemotherapy has recently become a primary systemic therapy recommended by NCCN guidelines for patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). However, most pts still do not respond to treatment, indicating a large unmet need for pts with unresectable disease. CMP-001 is a toll-like receptor 9 (TLR9) agonist comprising a CpG-A oligodeoxynucleotide packaged in a virus-like particle that can induce type I interferon secretion from tumor-associated plasmacytoid dendritic cells, promoting a Th1-like chemokine mili

APA, Harvard, Vancouver, ISO, and other styles

8

Monti, Matilde, Francesca Consoli, Raffaella Vescovi, Mattia Bugatti, and William Vermi. "Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma." Cells 9, no. 2 (2020): 417. http://dx.doi.org/10.3390/cells9020417.

Full text

Abstract:

The prognosis of metastatic melanoma (MM) patients has remained poor for a long time. However, the recent introduction of effective target therapies (BRAF and MEK inhibitors for BRAFV600-mutated MM) and immunotherapies (anti-CTLA-4 and anti-PD-1) has significantly improved the survival of MM patients. Notably, all these responses are highly dependent on the fitness of the host immune system, including the innate compartment. Among immune cells involved in cancer immunity, properly activated plasmacytoid dendritic cells (pDCs) exert an important role, bridging the innate and adaptive immune res

APA, Harvard, Vancouver, ISO, and other styles

9

Davar, Diwakar, Arivarasan Karunamurthy, Douglas Hartman, et al. "303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A330. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0303.

Full text

Abstract:

BackgroundNeoadjuvant PD-1 blockade produces major pathological responses (MPR) in ~30% of patients (pts) with high-risk resectable melanoma (MEL) with durable relapse-free benefit, and increased circulating activated CD8+ T cells.1 2 CMP-001 is a type A CpG packaged within a virus-like particle that activates tumor-associated plasmacytoid dendritic cells (pDC) via TLR9 inducing type I interferons and anti-tumor CD8+ T cells. CMP-001/pembrolizumab produces durable anti-tumor responses in PD-1 refractory melanoma.3 We previously reported preliminary evidence of efficacy of neoadjuvant IT CMP/Ni

APA, Harvard, Vancouver, ISO, and other styles

10

de Rosa, Francesco, Laura Ridolfi, Laura Fiammenghi, et al. "Dendritic cell vaccination for metastatic melanoma." Melanoma Research 27, no. 4 (2017): 351–57. http://dx.doi.org/10.1097/cmr.0000000000000356.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Chen, Vivien. "Dendritic-cell vaccination for metastatic melanoma?" Lancet Oncology 7, no. 5 (2006): 368. http://dx.doi.org/10.1016/s1470-2045(06)70678-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Charfi, Slim, Sameh Ellouze, Hela Mnif, Ali Amouri, Abdelmajid Khabir, and Tahya Sellami-Boudawara. "Plasmacytoid Melanoma of the Urinary Bladder and Lymph Nodes with Immunohistochemical Expression of Plasma Cell Markers Revealing Primary Esophageal Melanoma." Case Reports in Pathology 2012 (2012): 1–5. http://dx.doi.org/10.1155/2012/916256.

Full text

Abstract:

Plasmacytoid variant of melanoma is reported in only rare cases. We present the case of a 54-years-old man admitted for enlarged lymph nodes in the lumbar region. Initial diagnosis of plasmablastic lymphoma/plasma cell myeloma was considered. At our institute, a bladder polyp was removed. Microscopic exam demonstrated dense plasmacytoid cells infiltration with pigment deposits. Immunohistochemical study showed strong expression of HMB45, Melan A, and vimentin. There was focal positivity with S100 protein and CD138/syndecan-1. The diagnosis of metastatic plasmacytoid melanoma was finally establ

APA, Harvard, Vancouver, ISO, and other styles

13

Damiano, J. J., C. C. Patrone, L. D. Falo, L. H. Butterfield, J. M. Kirkwood, and L. J. Geskin. "361 Dendritic cell vaccines for metastatic melanoma." Journal of Investigative Dermatology 137, no. 5 (2017): S62. http://dx.doi.org/10.1016/j.jid.2017.02.378.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Dillman, Robert O., Senthamil R. Selvan, and Patric M. Schiltz. "Patient-Specific Dendritic-Cell Vaccines for Metastatic Melanoma." New England Journal of Medicine 355, no. 11 (2006): 1179–81. http://dx.doi.org/10.1056/nejmc061667.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Nesselhut, Jan, Dagmar Marx, Raymond Y. Chang, and Thomas Nesselhut. "Dendritic cell based immunotherapy in metastatic uveal melanoma." Journal of Clinical Oncology 36, no. 15_suppl (2018): e21526-e21526. http://dx.doi.org/10.1200/jco.2018.36.15_suppl.e21526.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Di Domizio, Jeremy, Olivier Demaria, and Michel Gilliet. "Plasmacytoid Dendritic Cells in Melanoma: Can We Revert Bad into Good?" Journal of Investigative Dermatology 134, no. 7 (2014): 1797–800. http://dx.doi.org/10.1038/jid.2014.155.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Wilson, Natalie, Catherine Mikol, Anna Donaldson, Daniel Fowler, and Angus Dalgleish. "Dendritic Cell Immunotherapy for Advanced Metastatic Melanoma: Interim Report." Journal of Immunotherapy 28, no. 6 (2005): 661. http://dx.doi.org/10.1097/01.cji.0000191106.88690.e1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Chen, Qing, Wang Liu, and Zhongbin Zhoa. "Indoleamine 2,3-Dioxygenase (IDO); Silenced Dendritic Cell Vaccine with Ipilimumab in Treating Metastatic Melanoma Patients: A Case Report." Journal of Clinical and Cellular Immunology 14, no. 3 (2023): 3. https://doi.org/10.35248/2155-9899.23.14.688.

Full text

Abstract:

Immunotherapy has revolutionized the treatment landscape for metastatic melanoma. This case report presents the clinical course of a patient with metastatic melanoma who received combination therapy with ipilimumab, a CTLA-4 checkpoint inhibitor, and an Indoleamine 2,3-Dioxygenase (IDO)-silenced Dendritic Cell (DC) vaccine. The treatment approach aimed to enhance antitumour immunity by blocking immune checkpoints and activating dendritic cells. The patient demonstrated a significant clinical response, indicating the diversification and potentiation of the antitumour effects. This case undersco

APA, Harvard, Vancouver, ISO, and other styles

19

Mikhaylova, I. N., M. N. Stakheyeva, I. Zh Shubina, et al. "The immune system contributes to the effectiveness of vaccine therapy in patients with metastatic melanoma." Siberian journal of oncology 22, no. 2 (2023): 43–55. http://dx.doi.org/10.21294/1814-4861-2023-22-2-43-55.

Full text

Abstract:

The aim of the study was to identify differences in the immune system parameters between metastatic melanoma patients who responded and did not respond to dendritic cell vaccination.Material and Methods. The study group included 20 patients with stage III–IV metastatic melanoma, who received vaccine therapy with dendritic cells (DC) in a prophylactic mode. The control groups included 13 patients who had symptoms of disease progression at the time of starting vaccine therapy, and 5 healthy donors. The DC-vaccine was prepared in the form of a suspension of the patient’s autologous dendritic cell

APA, Harvard, Vancouver, ISO, and other styles

20

Tel, Jurjen, Erik H. J. G. Aarntzen, Tetsuro Baba, et al. "Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients." Cancer Research 73, no. 3 (2013): 1063–75. http://dx.doi.org/10.1158/0008-5472.can-12-2583.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Aspord, Caroline, Marie-Therese Leccia, Dimitri Salameire, et al. "HLA-A*0201 + Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients." Journal of Investigative Dermatology 132, no. 10 (2012): 2395–406. http://dx.doi.org/10.1038/jid.2012.152.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Charles, Julie, Jérémy Di Domizio, Dimitri Salameire, et al. "Characterization of Circulating Dendritic Cells in Melanoma: Role of CCR6 in Plasmacytoid Dendritic Cell Recruitment to the Tumor." Journal of Investigative Dermatology 130, no. 6 (2010): 1646–56. http://dx.doi.org/10.1038/jid.2010.24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Fugere, Tyler, Brad Fugere, Fnu Amisha, et al. "Interdigitating Dendritic Cell Sarcoma and Indeterminate Dendritic Cell Tumor: Patient Characteristics, Prognostic Factors, and Survival Outcomes for Rare Dendritic Cell Neoplasms." Blood 142, Supplement 1 (2023): 5346. http://dx.doi.org/10.1182/blood-2023-187700.

Full text

Abstract:

Background Dendritic cells are nonlymphoid, nonphagocytic, antigen-presenting cells present in lymphoid and nonlymphoid tissue. There are 4 types of dendritic cells: follicular, interdigitating, Langerhans, and fibroblastic cells. The WHO 2022 classification system groups dendritic cell and histiocytic neoplasms into 3 categories: plasmacytoid dendritic cell neoplasms, Langerhans cell and other dendritic cell neoplasms, and histiocytic neoplasms. The 2nd category is subdivided into “Langerhans cells neoplasms” and “other dendritic cell neoplasms”, which contains indeterminate dendritic cell tu

APA, Harvard, Vancouver, ISO, and other styles

24

Geskin, Larisa J., James J. Damiano, Christina C. Patrone, Lisa H. Butterfield, John M. Kirkwood, and Louis D. Falo. "Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma." Melanoma Research 28, no. 3 (2018): 211–21. http://dx.doi.org/10.1097/cmr.0000000000000441.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Butterfield, Lisa H., Begonya Comin-Anduix, Lazar Vujanovic, et al. "Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma." Journal of Immunotherapy 31, no. 3 (2008): 294–309. http://dx.doi.org/10.1097/cji.0b013e31816a8910.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Chinchanikar, S., A. Hassan, and K. Lankachandra. "Metastatic Melanoma of Unknown Primary with Plasmacytoid Morphology Presenting as Acute Liver Failure." American Journal of Clinical Pathology 162, Supplement_1 (2024): S109—S110. http://dx.doi.org/10.1093/ajcp/aqae129.244.

Full text

Abstract:

Abstract Introduction/Objective Viral hepatitis, drug toxicity, and autoimmune disorders are common etiologies of acute liver failure (ALF). Very rarely, a cause like metastatic melanoma may present as a primary driver of ALF. Malignant melanoma is histologically diverse and plasmacytoid melanoma is an unusual variant that may present as a solitary tumor or metastatic disease. Methods/Case Report A 48-year-old female presented with 2 weeks of right upper quadrant pain, nausea, coffee ground emesis and bleeding per rectum. She had no history of liver disease or alcohol use. On presentation, AST

APA, Harvard, Vancouver, ISO, and other styles

27

Huijts, Charlotte M., Saskia J. Santegoets, Tamarah D. de Jong, Henk M. Verheul, Tanja D. de Gruijl, and Hans J. van der Vliet. "Immunological effects of everolimus in patients with metastatic renal cell cancer." International Journal of Immunopathology and Pharmacology 30, no. 4 (2017): 341–52. http://dx.doi.org/10.1177/0394632017734459.

Full text

Abstract:

The mammalian target of rapamycin (mTOR) is a crucial kinase present in all cells. Besides its role in the regulation of cell-growth, proliferation, angiogenesis, and survival of malignant tumors, mTOR additionally plays an important role in immune regulation by controlling the balance between effector T cells and regulatory T cells (Tregs). This critically affects the suppressive state of the immune system. Here, the systemic immunological effects of everolimus treatment were comprehensively investigated in five patients with metastatic renal cell cancer. In this hypothesis generating study,

APA, Harvard, Vancouver, ISO, and other styles

28

Nesselhut, J., D. Marx, R. Y. Chang, et al. "Immunotherapy with dendritic cells primed with an allogenic melanoma cell line in advanced metastatic melanoma." Journal of Clinical Oncology 26, no. 15_suppl (2008): 20026. http://dx.doi.org/10.1200/jco.2008.26.15_suppl.20026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Benitez-Ribas, Daniel, Gosse J. Adema, Gregor Winkels та ін. "Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after FcγRII-mediated uptake". Journal of Experimental Medicine 203, № 7 (2006): 1629–35. http://dx.doi.org/10.1084/jem.20052364.

Full text

Abstract:

Plasmacytoid dendritic cells (pDCs) contribute to innate antiviral immune responses by producing type I interferons. Although human pDCs can induce T cell responses upon viral infection, it remains unclear if pDCs can present exogenous antigens. Here, we show that human pDCs exploit FcγRII (CD32) to internalize antigen–antibody complexes, resulting in the presentation of exogenous antigen to T cells. pDCs isolated from melanoma patients vaccinated with autologous monocyte-derived peptide- and keyhold limpet hemocyanin (KLH)–loaded dendritic cells, but not from nonvaccinated patients or patient

APA, Harvard, Vancouver, ISO, and other styles

30

OSHITA, CHIE, MASAKO TAKIKAWA, AKIKO KUME, et al. "Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial." Oncology Reports 28, no. 4 (2012): 1131–38. http://dx.doi.org/10.3892/or.2012.1956.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Markov, Oleg V., Nadezhda L. Mironova, Sergey V. Sennikov, Valentin V. Vlassov, and Marina A. Zenkova. "Prophylactic Dendritic Cell-Based Vaccines Efficiently Inhibit Metastases in Murine Metastatic Melanoma." PLOS ONE 10, no. 9 (2015): e0136911. http://dx.doi.org/10.1371/journal.pone.0136911.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Boudewijns, Steve, Rutger H. T. Koornstra, Harm Westdorp, et al. "Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination." OncoImmunology 5, no. 8 (2016): e1201625. http://dx.doi.org/10.1080/2162402x.2016.1201625.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Bol, Kalijn F., Hanneke W. Mensink, Erik H. J. G. Aarntzen, et al. "Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients." American Journal of Ophthalmology 158, no. 5 (2014): 939–47. http://dx.doi.org/10.1016/j.ajo.2014.07.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Ribas, Antoni, Begoña Comin-Anduix, Bartosz Chmielowski, et al. "Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma." Clinical Cancer Research 15, no. 19 (2009): 6267–76. http://dx.doi.org/10.1158/1078-0432.ccr-09-1254.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Pachynski, Russell K., Brian A. Zabel, Holbrook E. Kohrt, et al. "The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses." Journal of Experimental Medicine 209, no. 8 (2012): 1427–35. http://dx.doi.org/10.1084/jem.20112124.

Full text

Abstract:

Infiltration of specialized immune cells regulates the growth and survival of neoplasia. Here, in a survey of public whole genome expression datasets we found that the gene for chemerin, a widely expressed endogenous chemoattractant protein, is down-regulated in melanoma as well as other human tumors. Moreover, high chemerin messenger RNA expression in tumors correlated with improved outcome in human melanoma. In experiments using the B16 transplantable mouse melanoma, tumor-expressed chemerin inhibited in vivo tumor growth without altering in vitro proliferation. Growth inhibition was associa

APA, Harvard, Vancouver, ISO, and other styles

36

Yang, De, Xiao-Qing Li, Md Masud Alam, Øystein Rekdal, and Joost J. Oppenheim. "Oncolytic peptide LTX-315 enhances anti-melanoma immunity by inducing MyD88-dependent maturation of dendritic cells." Journal of Immunology 204, no. 1_Supplement (2020): 91.5. http://dx.doi.org/10.4049/jimmunol.204.supp.91.5.

Full text

Abstract:

Abstract LTX-315 is a synthetic cationic oncolytic peptide with potent anticancer cytotoxicity. LTX-315 induces both immunogenic tumor cell death and the generation of tumor-specific immune response. Given the central role of dendritic cell (DC) maturation in the induction of antigen-specific immune responses, we investigated the effect of LTX-315 treatment on the maturation of tumor-infiltrating DCs (TiDCs) and the generation of anti-melanoma immunity. The results reveal that LTX-315 induces the maturation of DCs through three distinct mechanisms: 1) release of DAMPs/alarmins; 2) complexes of

APA, Harvard, Vancouver, ISO, and other styles

37

Gerlini, Gianni, Paola Di Gennaro, Giulia Mariotti, et al. "Indoleamine 2,3-Dioxygenase+ Cells Correspond to the BDCA2+ Plasmacytoid Dendritic Cells in Human Melanoma Sentinel Nodes." Journal of Investigative Dermatology 130, no. 3 (2010): 898–901. http://dx.doi.org/10.1038/jid.2009.307.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Gajewski, T., Y. Zha, B. Thurner, and G. Schuler. "Association of gene expression profile in metastatic melanoma and survival to a dendritic cell-based vaccine." Journal of Clinical Oncology 27, no. 15_suppl (2009): 9002. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.9002.

Full text

Abstract:

9002 Background: Emerging data suggests that features of the melanoma tumor microenvironment may determine the clinical outcome to immunotherapies. We recently have observed a gene expression signature that correlated with a favorable clinical outcome in response to an IL-12-based melanoma vaccine. Increased expression of chemokine genes and T cell transcripts, and decreased expression of genes associated with aggressive tumor biology, were observed in the favorable group. To determine whether these patterns were reproducible, gene expression profiling was performed from an independent vaccine

APA, Harvard, Vancouver, ISO, and other styles

39

Nguyen, Xuan Duc, Hermann Eichler, Antje Sucker, Udo Hofmann, Dirk Schadendorf, and Harald Kluter. "Collection of autologous monocytes for dendritic cell vaccination therapy in metastatic melanoma patients." Transfusion 42, no. 4 (2002): 428–32. http://dx.doi.org/10.1046/j.1525-1438.2002.00067.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Fay, J. W., H. Ueno, J. Connolly, J. Banchereau, and K. Palucka. "Durable clinical responses in patients with metastatic melanoma vaccinated with dendritic cells loaded with killed allogeneic melanoma cells." Journal of Clinical Oncology 24, no. 18_suppl (2006): 2576. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.2576.

Full text

Abstract:

2576 Background: We demonstrated that DCs loaded with killed allogeneic tumors can cross-prime tumor-specific naïve CD8+T cells in vitro. Clinically this approach would overcome HLA restriction inherent to peptide vaccines and allow diversification of immune responses including priming of many clones of CD8+ and CD4+ T cells. Methods: Twenty (20) patients with metastatic melanoma were vaccinated with autologous monocyte-derived DCs loaded with killed allogeneic Colo829 melanoma cell line. A total of 8 vaccines were administered at monthly intervals. DCs were generated from monocytes by culturi

APA, Harvard, Vancouver, ISO, and other styles

41

Thomas, R., J. Padmanabha, M. Chambers, et al. "Metastatic lesions in the joint associated with acute inflammatory arthritis after dendritic cell immunotherapy for metastatic melanoma." Melanoma Research 11, no. 2 (2001): 167–73. http://dx.doi.org/10.1097/00008390-200104000-00012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Lenogue, Kevin, Alexandre Walencik, Karine Laulagnier, et al. "Engineering a Human Plasmacytoid Dendritic Cell-Based Vaccine to Prime and Expand Multispecific Viral and Tumor Antigen-Specific T-Cells." Vaccines 9, no. 2 (2021): 141. http://dx.doi.org/10.3390/vaccines9020141.

Full text

Abstract:

Because dendritic cells are crucial to prime and expand antigen-specific CD8+ T-cells, several strategies are designed to use them in therapeutic vaccines against infectious diseases or cancer. In this context, off-the-shelf allogeneic dendritic cell-based platforms are more attractive than individualized autologous vaccines tailored to each patient. In the present study, a unique dendritic cell line (PDC*line) platform of plasmacytoid origin, already used to prime and expand antitumor immunity in melanoma patients, was improved thanks to retroviral engineering. We demonstrated that the clinic

APA, Harvard, Vancouver, ISO, and other styles

43

Porcelli, Letizia, Michele Guida, Simona De Summa, et al. "uPAR+ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients." Journal for ImmunoTherapy of Cancer 9, no. 5 (2021): e002372. http://dx.doi.org/10.1136/jitc-2021-002372.

Full text

Abstract:

BackgroundEmerging evidence has highlighted the importance of extracellular vesicle (EV)-based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic melanoma. Considering the tumor-promoting implications of urokinase-type plasminogen activator receptor (uPAR) signaling, this study aimed to assess uPAR expression in the plasma-derived EVs of patients with metastatic melanoma to determine its potential correlation with clinical outcomes.MethodsBlood samples from 71 patients with metastatic melanoma were collected before initiating immunotherapy. Tumor-derived and imm

APA, Harvard, Vancouver, ISO, and other styles

44

Paczesny, Sophie, Jacques Banchereau, Knut M. Wittkowski, Giovanna Saracino, Joseph Fay, and A. Karolina Palucka. "Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic Cells." Journal of Experimental Medicine 199, no. 11 (2004): 1503–11. http://dx.doi.org/10.1084/jem.20032118.

Full text

Abstract:

Cancer vaccines aim at inducing (a) tumor-specific effector T cells able to reduce/eliminate the tumor mass, and (b) long-lasting tumor-specific memory T cells able to control tumor relapse. We have shown earlier, in 18 human histocompatibility leukocyte antigen (HLA)-A*0201 patients with metastatic melanoma, that vaccination with peptide-loaded CD34–dendritic cells (DCs) leads to expansion of melanoma-specific interferon γ–producing CD8+ T cells in the blood. Here, we show in 9 out of 12 analyzed patients the expansion of cytolytic CD8+ T cell precursors specific for melanoma differentiation

APA, Harvard, Vancouver, ISO, and other styles

45

Barbour, Angela H., and Brendon J. Coventry. "Dendritic cell density and activation status of tumour-infiltrating lymphocytes in metastatic human melanoma." Melanoma Research 13, no. 3 (2003): 263–69. http://dx.doi.org/10.1097/00008390-200306000-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Moreira, Alvaro, Stefanie Gross, Ugur Uslu, et al. "Dendritic cell vaccination in metastatic uveal melanoma as compassionate treatment: Immunological and clinical responses." Journal of Clinical Oncology 37, no. 15_suppl (2019): e21024-e21024. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e21024.

Full text

Abstract:

e21024 Background: Other than cutaneous melanoma, metastatic uveal melanoma (UM) is minimally responsive to checkpoint inhibitors. The prognosis remains very poor with mortality rates nearly unchanged over the last decades. The recently growing insight that immunotherapy significantly improves outcomes for cancer patients led to a re-emergence of vaccines including dendritic cell (DC) vaccines. Methods: We vaccinated an UM patient in a compassionate use setting and assessed the immunological and clinical responses. Based on this experience we performed individual compassionate treatments in ot

APA, Harvard, Vancouver, ISO, and other styles

47

Berard, Frederic, Patrick Blanco, Jean Davoust, et al. "Cross-Priming of Naive Cd8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells." Journal of Experimental Medicine 192, no. 11 (2000): 1535–44. http://dx.doi.org/10.1084/jem.192.11.1535.

Full text

Abstract:

The goal of tumor immunotherapy is to elicit immune responses against autologous tumors. It would be highly desirable that such responses include multiple T cell clones against multiple tumor antigens. This could be obtained using the antigen presenting capacity of dendritic cells (DCs) and cross-priming. That is, one could load the DC with tumor lines of any human histocompatibility leukocyte antigen (HLA) type to elicit T cell responses against the autologous tumor. In this study, we show that human DCs derived from monocytes and loaded with killed melanoma cells prime naive CD45RA+CD27+CD8+

APA, Harvard, Vancouver, ISO, and other styles

48

Samoylenko, Igor, Tatiana Zabotina, Irina N. Mikhaylova, et al. "Biochemical and immunologic markers in patients with metastatic melanoma treated with chemotherapy and dendritic cell vaccine." Journal of Clinical Oncology 31, no. 15_suppl (2013): e20042-e20042. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e20042.

Full text

Abstract:

e20042 Background: The purpose of this sub study was to identify peripheral blood biomarkers associated with the therapeutic effect of immunotherapy with dendritic cell vaccine in patients with metastatic melanoma (MM). Methods: Patients (pts) with low disease burden achieved disease control after two cycles of chemo (cisplatine, vinbalstie, DTIC) were randomized dendritic cell vaccine (DC) or three cycles of chemo. Vaccination schedule consisted of 5 subcutaneous injections of dendritic cell (DC) vaccine (2×106 cells pulsed with autologous lysate) with 14 days intervals. S100B level, LDH leve

APA, Harvard, Vancouver, ISO, and other styles

49

Meyer, Christiane, Laurene Cagnon, Nicole Montandon, et al. "Preferential enrichment of myeloid-derived suppressor cell subsets in patients with metastatic melanoma." Journal of Clinical Oncology 30, no. 15_suppl (2012): e19050-e19050. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e19050.

Full text

Abstract:

e19050 Background: Myeloid derived suppressor cells (MDSC) are key immunosuppressive cells enriched in peripheral blood during chronic inflammation. While these cells have been extensively studied in mice, their human counterparts are less well characterized. Several MDSC populations have been identified in cancer patients, depending on tumor type and experimental settings. MDSC include immature macrophages, granulocytes and dendritic cells, at different degree of maturation, from immature CD33+, to mature CD14+ and CD15+HLA-DR- cells. The goal of this study was to characterize myeloid cells i

APA, Harvard, Vancouver, ISO, and other styles

50

Heeren, Anne Marijne, Jossie Rotman, Sanne Samuels, et al. "Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth." Journal for ImmunoTherapy of Cancer 9, no. 10 (2021): e003623. http://dx.doi.org/10.1136/jitc-2021-003623.

Full text

Abstract:

BackgroundTherapeutic immune intervention is highly dependent on the T-cell priming and boosting capacity of tumor-draining lymph nodes (TDLN). In vulvar cancer, in-depth studies on the immune status of (pre)metastatic TDLN is lacking.MethodsWe have phenotyped and enumerated various T-cell and myeloid subsets in tumor-free (LN−, n=27) and metastatic TDLN (LN+, n=11) using flow cytometry. Additionally, we studied chemokine and cytokine release profiles and assessed expression of indoleamine 2,3-dioxygenase (IDO) in relation to plasmacytoid dendritic cell (pDC) or myeloid subsets.ResultsMetastat

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!